CALA - Watch for Continued Losses in Shares of Calithera Biosciences Inc. (CALA)

Calithera Biosciences Inc. (NASDAQ:CALA) traded today at a new 52-week low of $1.78. This new low was reached on approximately average trading volume as 760,000 shares traded hands, while the average 30-day volume is approximately 1 million shares.

There is potential upside of 14.2% for shares of Calithera Biosciences Inc. based on a current price of $1.95 and an average consensus analyst price target of $2.23.

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Over the past year, Calithera Biosciences Inc. has traded in a range of $1.78 to $6.18 and is now at $1.95.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer